- Home
- FBRT vs JANX Comparison
FBRT vs JANX Comparison
Compare FBRT & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBRT | JANX |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 882.8M | 790.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FBRT | JANX |
|---|---|---|
| Price | $8.58 | $13.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $13.50 | ★ $53.60 |
| AVG Volume (30 Days) | ★ 1.2M | 802.6K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 16.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $12.34 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | $13.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.40 | $12.12 |
| 52 Week High | $13.15 | $35.34 |
Technical Indicators
Market Signals| Indicator | FBRT | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 34.04 | 47.70 |
| Support Level | $8.42 | $13.12 |
| Resistance Level | $9.23 | $13.79 |
| Average True Range (ATR) | 0.24 | 0.51 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 12.23 | 25.89 |
Price Performance
Historical ComparisonAbout FBRT Franklin BSP Realty Trust Inc.
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.